Give a medicines decision a route into practice.
A medicines opportunity can involve pharmacy, clinical services, procurement, finance and digital teams before it reaches the people who need to act. Each sees an essential part of the case. The work is to keep those parts connected.
PHARMORIS, NEUVIOR’s Medicines Action Layer, is being developed around that challenge. Our health-system proposition centres on a defined medicines decision, the professional review it needs and the practical work required to introduce and examine a change. It gives a potential evaluation a clear purpose for the organisation considering it.
In the conversation.
NEUVIOR and our founder’s perspectives have appeared across science, business and technology publications.
Reporting, commentary, letters and podcast appearances | Read each feature for its format and source.
Start where the organisation feels the friction.
A chief pharmacist may need a clearer view of an implementation proposal. A formulary team may be preparing a case that needs several rounds of clarification. Operational colleagues may know which resource assumption will be difficult to deliver. Finance needs a comparison it can interrogate.
Identify the decision and the consequence of leaving it unresolved. Is the team missing evidence, an agreed interpretation, professional capacity or an owner for the next action? This makes the proposition useful from the beginning. A broad ambition for AI becomes a task with responsible people, an existing process and a result that could change what the organisation does next.
Put the scale in the right context.
NHSBSA estimates that NHS commissioners in England spent £21.4 billion on medicines, appliances, dressings and medical devices in calendar 2025, after central rebates. The scale gives medicines decisions real organisational significance.
It does not establish that a particular share is avoidable or recoverable by software. A local case needs the relevant period, activity, costs and comparison. It also needs to include the resources required to make a change. The commercial opportunity for PHARMORIS is to help examine a defined evidence-to-action problem and demonstrate useful work within that setting, rather than apply a national percentage to an untested savings promise.
Bring the people who own the whole case.
Pharmacy-led users may prepare and review the evidence. Clinical and operational leaders shape what is appropriate and deliverable. The authorised budget holder and procurement route determine how an evaluation or service can be commissioned.
In England, NHS guidance identifies the ICB Chief Pharmacist or Director of Medicines and Pharmacy as the system clinical lead for medicines optimisation, with executive accountability and collaborative governance. Provider and system roles still need to be established locally. In Scotland, the discussion belongs with the relevant Health Board and procurement arrangements; medicine-supply contracts and a software evaluation are not automatically the same buying route. The briefing should clarify authority as well as interest.
Examine one medicines opportunity properly.
Consider a provider team assessing a generic-medicines opportunity. A price comparison may make the proposal interesting, while clinical appropriateness, supply conditions, local practice, communication and professional capacity determine what can actually be introduced.
A proposed evaluation could follow the case from preparation through review and implementation planning. It would examine source quality, assumptions, the effort of resolving questions and the work required from participating teams. A later comparison would distinguish what was agreed from what was introduced and observed. This illustrative case explains the evaluation direction without presuming a deployment, an automatic switch or a financial result.
Make the implementation cost visible early.
A change may require training, coordination, source checking and ongoing support. Some costs sit with the adopting organisation, while others sit with the supplier. A programme can appear attractive when only the headline opportunity is counted.
Bring these demands into the same discussion as the proposed benefit. Which teams need to contribute? What might slow the work? Would a smaller first case answer the question more efficiently? A hospital or system buyer should be able to understand the intended value, the work carried locally and the conditions under which expansion would make sense. These are the foundations of an evaluation that can inform an actual decision.
Build evidence that can travel responsibly.
Our planned evaluation questions concern the complete workflow: the quality of the case, professional effort, implementation follow-through and the economics of use. The comparator should reflect competent existing practice and include the burden of adopting the approach.
A result from one team may identify a useful pattern without proving the same effect everywhere. Explain the setting, what changed and which conditions mattered. That helps another organisation judge relevance and helps development identify what can be reused. The goal is a stronger basis for further evaluation, repeat use or a decision to concentrate on a more suitable task.
Hospital outpatient options comparison.
A proposed comparison of medicines-service options, bringing expected benefit, delivery costs and conditions for success into the same decision. Hospital and provider economics would remain separate, so each side can see who carries the work, who receives the benefit and what would make the option worthwhile.
An option may create value for a provider while adding work or cost inside the hospital. A useful comparison keeps each party’s starting point visible and examines the conditions on which the expected benefit depends. That gives the organisation a more revealing choice than a single blended headline.
Bring the case your organisation needs to move.
We welcome chief pharmacists, medicines teams, clinical and operational leaders, finance colleagues and authorised buyers with a consequential medicines question. Tell us the task, its owner, the current approach and the decision a better comparison would support.
A PHARMORIS briefing can examine a focused evaluation proposition, the relevant review participants and the evidence required for a next step. A clear sponsor, appropriate information and a worthwhile question give the discussion substance.